This data strengthens SGT-003's differentiation and supports potential for accelerated approval. Traders should monitor upcoming FDA meetings in H1 2026 for guidance on accelerated approval pathway and mid-2026 clinical updates.
SLDB drugs
SLDB drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 12 $7.71entry
- T+1 · 8mo ago −5.19%α −4.59% · $7.31
- T+5 · 8mo ago −7.65%α −6.67% · $7.12
- T+20 · 7mo ago +4.02%α +2.05% · $8.02
- T+60 · 5mo ago −13.10%α −23.80% · $6.70
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Solid Biosciences announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, showing robust microdystrophin expression and biomarker improvements in Duchenne muscular dystrophy patients. The company also confirmed FDA alignment on the Phase 3 IMPACT DUCHENNE trial design, with dosing expected to begin in Q1 2026.
Key Facts
- SGT-003 showed 60% mean microdystrophin expression by western blot at Day 90 (n=19), increasing to 91% at Day 360 (n=3)
- Mean vector copies per nucleus were 11 at Day 90 and 12 at Day 360, indicating stable transduction
- Key biomarkers showed significant improvement: 38% mean reduction in serum creatine kinase (CK) at Day 90, 44% reduction in eMHC-positive fibers suggesting disruption of degeneration-regeneration cycle
- FDA has agreed the Phase 3 IMPACT DUCHENNE trial design is reasonable, with dosing expected in Q1 2026
- SGT-003 is the only microdystrophin therapy with the R16/R17 binding domain that localizes nNOS to muscle
Financial Impact
No direct financial impact disclosed, but clinical progress significantly de-risks development path for SGT-003
Risk Factors
- Interim data from small samples (n=3 at Day 360) may not be predictive of final outcomes
- Phase 3 trial results may not replicate Phase 1/2 findings
- Company remains dependent on raising substantial additional capital to continue development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-102489 |
| Document: 0001193125-26-102489-index-headers.html | 0001193125-26-102489 |
| Document: 0001193125-26-102489-index.html | 0001193125-26-102489 |
| Document: 0001193125-26-102489.txt | 0001193125-26-102489 |
Track record
14 reports on SLDB
4 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +20.77% at T+20 after the Mar 19, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.84 Now $6.48 −5.26% settles Dec 15
- Nov 6, 202610d ago SC 13D/A Neutral 3/10 Entry $7.02 Now $6.48 −7.69% settles Dec 8
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $6.18 Now $6.48 +4.85% settles Dec 4
- Aug 6, 202614w ago S-3ASR Neutral 4/10 Entry $8.39 to $10.25 Now $6.48 −22.77% ▲ +22.17% +22.57% vs SPY
- May 12, 202626w ago Press Release Bearish 6/10 Entry $7.38 to $7.22 Now $6.48 +12.20% ▲ +2.17% +1.56% vs SPY
- May 7, 202627w ago Press Release Bullish 7/10 Entry $7.07 to $6.85 Now $6.48 −8.35% ▼ −3.11% −6.25% vs SPY
- Apr 23, 202629w ago DEFA14A Neutral 3/10 Entry $7.92 to $6.50 Now $6.48 −18.18% ▼ −17.93% −21.96% vs SPY
- Apr 10, 202631w ago 8-K Neutral 2/10 Entry $8.39 to $7.68 Now $6.48 −22.77% ▼ −8.46% −16.19% vs SPY
- Apr 1, 202632w ago EFFECT Bearish 7/10 Entry $7.38 to $7.05 Now $6.48 +12.20% ▲ +4.47% +14.19% vs SPY
- Mar 19, 202634w ago Press Release Bullish 8/10 Entry $7.03 to $8.49 Now $6.48 −7.82% ▲ +20.77% +11.45% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers